Background: PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for recurrent/refractory (r/r) disease. Response rates (ORR) range between 30-60% with a progression free survival (PFS) of 2-5 months. Ibrutinib has shown promising clinical response in some B-cell malignancies. This trial investigates Ibrutinib in patients with r/r PCNSL and SCNSL. Methods: Eligible patients had r/r PCNSL or SCNSL, age ? 18, ECOG ?
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile